{"id":70740,"date":"2026-05-12T10:25:30","date_gmt":"2026-05-12T10:25:30","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70740"},"modified":"2026-05-21T07:14:10","modified_gmt":"2026-05-21T07:14:10","slug":"ghrp-2","status":"publish","type":"product","link":"https:\/\/medsbase.com\/sv\/product\/ghrp-2\/","title":{"rendered":"GHRP-2 Acetat"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Quick Answer \u2014 What is GHRP-2 Acetate?<\/h3>\n<p style=\"margin: 0;\"><strong>GHRP-2 Acetat<\/strong> (also called Pralmorelin or KP-102) is a 6-amino-acid synthetic hexapeptide growth hormone secretagogue and the most potent first-generation member of the GHRP series on a per-mg basis. It acts on the growth hormone secretagogue receptor (GHS-R1a) \u2014 the same receptor as endogenous ghrelin and as <a href=\"https:\/\/medsbase.com\/sv\/ghrp-6\/\">GHRP-6<\/a> \u2014 producing pulsatile GH release with a smaller appetite signal than GHRP-6 but a similar cortisol\/prolactin profile. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Vad du f\u00e5r med MedsBase:<\/strong> Forskningsgrad av liofiliserade peptider \u00b7 HPLC \u226599% renhet (COA p\u00e5 beg\u00e4ran) \u00b7 Diskret temperaturstabil f\u00f6rpackning \u00b7 Peptidbud \u00f6ver hela v\u00e4rlden \u00b7 1 400+ verifierade <a href=\"https:\/\/medsbase.com\/sv\/reviews\/\">kundrecensioner<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r <a href=\"https:\/\/medsbase.com\/sv\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifikation<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalj<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS-nummer<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">158861-67-7 (GHRP-2 free base); supplied as the acetate salt form<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molekylformel<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>45<\/sub>H<sub>55<\/sub>N<sub>9<\/sub>O<sub>6<\/sub> (free base; acetate salt adds CH<sub>3<\/sub>COOH counterion)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molekylvikt<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">817.97 Da (free base)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sekvens<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH<sub>2<\/sub> (6 amino acids; contains D-Ala at position 1, D-2-naphthylalanine at position 2, and D-Phe at position 5 for proteolytic stability; C-terminally amidated). Also known as Pralmorelin \/ KP-102.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Form<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized acetate salt (white to off-white powder)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Renhet<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (HPLC-verifierat, COA p\u00e5 beg\u00e4ran)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f6rvaring<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofiliserat: 2\u20138 \u00b0C (kylsk\u00e5p) f\u00f6r arbetslager; \u221220 \u00b0C f\u00f6r l\u00e5ngtidslagring av o\u00f6ppnade flaskor. Rekonstituerat: 2\u20138 \u00b0C, anv\u00e4nd inom ~30 dagar. Skydda fr\u00e5n ljus. Frys inte upp och tina den rekonstituerade l\u00f6sningen.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>L\u00f6slighet<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Bakteriostatisk vatten (rekommenderas) eller sterilt vatten f\u00f6r kortare anv\u00e4ndningsperioder<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forskningsanv\u00e4ndning<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Endast f\u00f6r laboratorieforskning. Ej avsedd f\u00f6r diagnostiskt eller terapeutiskt bruk p\u00e5 m\u00e4nniskor eller djur.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>What Is GHRP-2 Acetate?<\/h2>\n<p><strong>GHRP-2<\/strong> (Growth Hormone Releasing Peptide 2), also known as <strong>Pralmorelin<\/strong> or by its original developmental code <strong>KP-102<\/strong>, is a 6-amino-acid synthetic hexapeptide and one of the canonical first-generation members of the growth hormone secretagogue (GHS) peptide class. It was developed shortly after GHRP-6 in the same Bowers structure-activity-relationship programme at Tulane University, with a focus on increasing per-mg potency relative to the parent compound while preserving the GHS-R1a-selective receptor profile. The acetate counterion is used in research-grade lyophilization because it improves long-term peptide stability and aqueous solubility without altering pharmacology.<\/p>\n<p>The well-characterised sequence is D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH<sub>2<\/sub>, molecular weight 817.97\u00a0Da, empirical formula C<sub>45<\/sub>H<sub>55<\/sub>N<sub>9<\/sub>O<sub>6<\/sub>. The structural innovation relative to GHRP-6 is the introduction of D-2-naphthylalanine (D-2-Nal) at position 2 in place of D-Trp \u2014 the more lipophilic naphthyl ring increases GHS-R1a affinity and produces approximately 2\u20133-fold greater per-mg GH-releasing potency in published research. The two D-amino-acid substitutions (D-Ala at position 1, D-Phe at position 5) confer protease resistance. Notably, in Japan GHRP-2 (under the name Pralmorelin Hydrochloride \/ GHRP Kaken) was approved as a single-use intravenous diagnostic agent for adult growth hormone deficiency testing \u2014 one of the only GHS peptides to reach any form of clinical approval. GHRP-2 remains <strong>inte godk\u00e4nt<\/strong> by the FDA, EMA, MHRA, or any other Western regulator for therapeutic use. The research-grade GHRP-2 acetate sold here is supplied <strong>endast f\u00f6r laboratorieforsknings\u00e4ndam\u00e5l<\/strong> and is not intended for human or veterinary administration.<\/p>\n<h2>Mechanism of Action \u2014 GHS-R1a Receptor Agonism with Enhanced Potency<\/h2>\n<p>What makes GHRP-2 mechanistically distinctive among first-generation growth hormone secretagogues is the combination of <strong>high GHS-R1a affinity with a relatively short plasma half-life<\/strong>, producing a sharper and more reproducible GH pulse in published research:<\/p>\n<ul>\n<li><strong>GHS-R1a receptor agonism on somatotrophs<\/strong> \u2014 GHRP-2 binds the growth hormone secretagogue receptor type 1a (GHS-R1a, the ghrelin receptor) on anterior-pituitary somatotrophs. Receptor activation couples to G\u03b1<sub>q\/11<\/sub> and phospholipase C, raising intracellular calcium and triggering exocytosis of GH-containing vesicles. The substitution of D-2-Nal at position 2 produces approximately 2\u20133-fold higher receptor occupancy at equivalent doses compared with GHRP-6 in radioligand-binding assays, translating into a larger GH pulse per unit dose.<\/li>\n<li><strong>Somatostatin tone suppression<\/strong> \u2014 Like other GHRPs, GHRP-2 acts both at the somatotroph and at hypothalamic neurons that release somatostatin. By suppressing tonic somatostatin inhibition simultaneously with stimulating somatotroph release, the peptide produces a larger net GH pulse than direct pituitary stimulation alone would predict. This dual action is the canonical mechanism of the GHRP class and underlies the synergy with GHRH analogs described below.<\/li>\n<li><strong>Synergy with GHRH-receptor agonists<\/strong> \u2014 The GHS-R and GHRH-R pathways converge intracellularly but use different second-messenger systems (PLC\/IP<sub>3<\/sub>\/Ca<sup>2+<\/sup> vs adenylyl cyclase\/cAMP\/PKA), so GHRP-2 and GHRH analogs produce additive or synergistic GH release when combined. The canonical research protocol pairs GHRP-2 with a GHRH analog such as <a href=\"https:\/\/medsbase.com\/sv\/sermorelin\/\">Sermorelin<\/a> eller <a href=\"https:\/\/medsbase.com\/sv\/cjc-1295-with-dac\/\">CJC-1295 med DAC<\/a> for maximal pulsatile GH research stimulus. The &#8220;GHRP-2 + GHRH&#8221; challenge is also the basis for the Japanese clinical use of Pralmorelin in GH-deficiency diagnostic testing.<\/li>\n<\/ul>\n<p>GHRP-2 produces a smaller appetite signal than GHRP-6 in head-to-head rodent and human research \u2014 the D-2-Nal substitution at position 2 reduces but does not eliminate the orexigenic activity inherited from ghrelin-receptor agonism. The cortisol and prolactin signals remain present at levels comparable to GHRP-6, which is the principal research-relevant confound that newer receptor-selective analogs (Ipamorelin) were designed to eliminate. Plasma half-life is approximately 15\u201320 minutes \u2014 shorter than GHRP-6 (~30\u201360 min) \u2014 which produces a sharper and more reproducible GH pulse but requires more frequent dosing for sustained-stimulus research protocols.<\/p>\n<h2>Publicerade forskningsapplikationer<\/h2>\n<p>GHRP-2 is used in laboratory research contexts that investigate:<\/p>\n<ul>\n<li><strong>Growth hormone axis pharmacology<\/strong> \u2014 pulsatile GH dynamics, somatotroph dose-response, comparative GHS potency assays; benchmark high-potency first-generation GHS in published GH-axis literature (Bowers, J Clin Endocrinol Metab; Ghigo et al., J Clin Endocrinol Metab)<\/li>\n<li><strong>GH-deficiency diagnostic research<\/strong> \u2014 GHRP-2 stimulation testing for adult GH deficiency (the Japanese clinical use case), GHRP-2 + GHRH combined-challenge testing, somatotroph reserve characterisation in preclinical models<\/li>\n<li><strong>Pituitary function research<\/strong> \u2014 GH reserve testing, somatotroph hypertrophy \/ hyperplasia, mechanism-of-action research for novel GH secretagogues<\/li>\n<li><strong>Cachexia and wasting syndrome research<\/strong> \u2014 tumour-bearing rodent cachexia, COPD-associated wasting, aging-related sarcopenia models; smaller appetite signal than GHRP-6 makes GHRP-2 useful when food-intake is a confound<\/li>\n<li><strong>Ghrelin-axis pharmacology<\/strong> \u2014 reduced but non-zero appetite signal; useful research arm for separating GHS-R-mediated appetite from GH-axis effects<\/li>\n<li><strong>Comparative GHS research<\/strong> \u2014 head-to-head benchmarking against <a href=\"https:\/\/medsbase.com\/sv\/ghrp-6\/\">GHRP-6<\/a> (first-generation sibling), <a href=\"https:\/\/medsbase.com\/sv\/ipamorelin\/\">Ipamorelin<\/a> (third-generation receptor-selective), hexarelin, and orally-active small-molecule GHS such as MK-677<\/li>\n<li><strong>Combined GHRP + GHRH research<\/strong> \u2014 canonical &#8220;GHRP-2 + GHRH&#8221; synergistic protocol for maximal GH-pulse research stimulus, pairing GHRP-2 with <a href=\"https:\/\/medsbase.com\/sv\/sermorelin\/\">Sermorelin<\/a> eller <a href=\"https:\/\/medsbase.com\/sv\/cjc-1295-with-dac\/\">CJC-1295 med DAC<\/a>.<\/li>\n<\/ul>\n<p>For broader context on where GHRP-2 fits within the growth-axis peptide landscape, see <a href=\"https:\/\/medsbase.com\/sv\/ghrp-6\/\">GHRP-6<\/a> as the first-generation sibling, <a href=\"https:\/\/medsbase.com\/sv\/ipamorelin\/\">Ipamorelin<\/a> as the receptor-selective newer analog, and <a href=\"https:\/\/medsbase.com\/sv\/cjc-1295-with-dac\/\">CJC-1295 med DAC<\/a> as the canonical synergistic GHRH partner. Browse the full <a href=\"https:\/\/medsbase.com\/sv\/peptides\/\">forskningspeptidkatalogen<\/a> f\u00f6r relaterade f\u00f6reningar.<\/p>\n<h2>Tillg\u00e4ngliga styrkor och koncentrationer<\/h2>\n<p>MedsBase stocks GHRP-2 Acetate in two lyophilized vial sizes calibrated to typical research protocol lengths. Each strength is available in 10-vial or 20-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Flaskstyrka<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Typiskt forskningsanv\u00e4ndningsfall<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">F\u00f6rpackningsstorlekar<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard research strength \u2014 short-cycle GH-pulse protocols, single-cohort studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 eller 20 flaskor<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle protocols, multi-cohort studies, lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 eller 20 flaskor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized acetate-salt powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when researchers want to minimise injection volume in rodent protocols. Because GHRP-2 dose ranges are in the 100\u2013500\u00a0mcg per administration regime, a single 5\u00a0mg vial supports many weeks of research at typical doses.<\/p>\n<h2>How It Compares \u2014 GHRP-2 vs GHRP-6<\/h2>\n<p>GHRP-2 and <a href=\"https:\/\/medsbase.com\/sv\/ghrp-6\/\">GHRP-6<\/a> are the two canonical first-generation hexapeptide growth hormone secretagogues from the Bowers laboratory programme. They share the same receptor (GHS-R1a) and the same six-residue hexapeptide architecture, differing primarily in the amino acid at position 2 \u2014 D-2-naphthylalanine in GHRP-2 versus D-tryptophan in GHRP-6. This single substitution accounts for most of the pharmacological differences observed in published research.<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Kriterium<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">GHRP-2 (Pralmorelin)<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">GHRP-6<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>L\u00e4ngd<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">6 amino acids (hexapeptide)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">6 amino acids (hexapeptide)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Position 2 residue<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">D-2-naphthylalanine (D-2-Nal)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">D-tryptophan (D-Trp)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Per-mg potency<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2\u20133\u00d7 more potent<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Baseline first-generation potency<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Appetite signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Reduced (still present, smaller than GHRP-6)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Strong (ghrelin-like orexigenic effect)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Cortisol \/ prolactin<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Modest increases (comparable to GHRP-6)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Modest increases<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Plasma half-life<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15\u201320 min<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~30\u201360 min<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typisk forskningsdos<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">100\u2013500\u00a0mcg, 1\u20133x daily<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">50\u2013300\u00a0mcg, 1\u20133x daily<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Clinical use<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GH-deficiency diagnostic test (Japan only)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">None approved anywhere<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For research where appetite stimulation is part of the target endpoint (cachexia models, food-intake studies), GHRP-6 is the conventional choice because the orexigenic signal is stronger. For research where the appetite confound is a concern but cortisol\/prolactin tolerability is acceptable, GHRP-2 produces a sharper GH pulse with less feeding-behaviour interference. For the cleanest possible GH-axis pharmacology where cortisol and prolactin must be controlled, <a href=\"https:\/\/medsbase.com\/sv\/ipamorelin\/\">Ipamorelin<\/a> (third-generation selective analog) is the receptor-selective alternative.<\/p>\n<h2>F\u00f6rvaring och rekonstitution<\/h2>\n<p><strong>F\u00f6rberedelse f\u00f6re rekonstitution:<\/strong> store lyophilized vials refrigerated at 2\u20138\u00a0\u00b0C in original packaging for short-term working stock. For unopened long-term storage, freeze at \u221220\u00a0\u00b0C. Lyophilized GHRP-2 acetate is stable under refrigeration for up to 24 months and at \u221220\u00a0\u00b0C for up to 36 months. Avoid freeze-thaw cycles on the lyophilized powder.<\/p>\n<p><strong>Rekonstitutionsprocedur:<\/strong> inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers a 100\u00a0mcg research dose; 0.1\u00a0mL delivers 250\u00a0mcg. Swirl gently \u2014 do <strong>inte<\/strong> Skaka \u2014 och l\u00e5t st\u00e5 i 2\u20135 minuter f\u00f6r fullst\u00e4ndig uppl\u00f6sning. En korrekt rekonstituerad l\u00f6sning b\u00f6r vara klar och f\u00e4rgl\u00f6s.<\/p>\n<p><strong>f\u00f6rvara l\u00f6sningen i kylsk\u00e5p vid 2\u20138 \u00b0C och anv\u00e4nd inom 30 dagar f\u00f6r optimal stabilitet. Frys inte den rekonstituerade l\u00f6sningen \u2014 frys-tina-cykler f\u00f6rs\u00e4mrar peptidens integritet. Kasta eventuella flaskor som visar oklarhet, f\u00e4llning eller f\u00e4rgf\u00f6r\u00e4ndring.<\/strong> F\u00f6rvara kyld vid 2\u20138 \u00b0C och anv\u00e4nd inom 30 dagar f\u00f6r optimal stabilitet. Frys inte den rekonstituerade l\u00f6sningen \u2014 frys-t\u00f6a-cykler f\u00f6rs\u00e4mrar peptidens integritet. Kasta alla flaskor som visar grumlighet, f\u00e4llning eller f\u00e4rgf\u00f6r\u00e4ndring.<\/p>\n<h2 id=\"faqs\">Vanliga fr\u00e5gor<\/h2>\n<h3>What is GHRP-2 used for in research?<\/h3>\n<p>GHRP-2 is used in laboratory research investigating the growth hormone axis, pulsatile GH release dynamics, somatotroph dose-response characterisation, GH-deficiency diagnostic protocols, ghrelin-axis pharmacology, cachexia and wasting syndrome models, and combined GHRP + GHRH synergistic GH-release protocols. It is the most potent first-generation GHS research peptide on a per-mg basis. The research-grade GHRP-2 sold here is <strong>inte<\/strong> FDA-approved (except for the diagnostic indication in Japan) and is supplied strictly for laboratory research use only.<\/p>\n<h3>How is GHRP-2 different from GHRP-6?<\/h3>\n<p>Both are first-generation hexapeptide growth hormone secretagogues that act on the same GHS-R1a receptor, but they differ in the amino acid at position 2 \u2014 D-2-naphthylalanine in GHRP-2 versus D-tryptophan in GHRP-6. This single substitution makes GHRP-2 about 2\u20133\u00d7 more potent on a per-mg basis and produces a smaller appetite signal. Both peptides retain the modest cortisol\/prolactin signal that newer receptor-selective analogs (such as Ipamorelin) were designed to eliminate. Plasma half-life is shorter for GHRP-2 (~15\u201320 min) vs GHRP-6 (~30\u201360 min).<\/p>\n<h3>What is the difference between GHRP-2 and Pralmorelin?<\/h3>\n<p>They are the same compound under different names. &#8220;GHRP-2&#8221; is the research-literature designation; &#8220;Pralmorelin&#8221; is the international nonproprietary name (INN); &#8220;KP-102&#8221; was the original Kaken Pharmaceutical developmental code. The compound was approved in Japan under the Pralmorelin name as a single-use intravenous diagnostic test for adult growth hormone deficiency \u2014 the only Western-style regulatory approval of any GHRP-series peptide to date.<\/p>\n<h3>What is the typical GHRP-2 research dose?<\/h3>\n<p>Published preclinical protocols typically use 100\u2013500\u00a0mcg per administration, given subcutaneously 1\u20133 times daily for 2\u201312 week research cycles. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 0.04\u00a0mL equals 100\u00a0mcg, 0.1\u00a0mL equals 250\u00a0mcg. The Japanese diagnostic-test dose is 100\u00a0mcg intravenously as a single administration.<\/p>\n<h3>Is GHRP-2 FDA approved?<\/h3>\n<p>No. GHRP-2 is not approved by the FDA, EMA, MHRA, or any other Western regulator for human therapeutic or diagnostic use. It is approved in Japan under the name Pralmorelin Hydrochloride \/ GHRP Kaken as a single-use intravenous diagnostic agent for adult growth hormone deficiency testing. All GHRP-2 sold by research-use-only suppliers outside Japan is for laboratory investigation and should not be administered to humans.<\/p>\n<h3>How should GHRP-2 Acetate be stored?<\/h3>\n<p>Lyofiliserade flaskor: f\u00f6rvaras i kylsk\u00e5p vid 2\u20138 \u00b0C f\u00f6r korttidslager eller vid \u221220 \u00b0C f\u00f6r l\u00e5ngtidsf\u00f6rvaring av o\u00f6ppnade flaskor. Rekonstituerad l\u00f6sning: f\u00f6rvaras i kylsk\u00e5p vid 2\u20138 \u00b0C, anv\u00e4nds inom 30 dagar. Frys inte den rekonstituerade l\u00f6sningen \u2014 frys-t\u00f6-cykler f\u00f6rs\u00e4mrar peptiden. Skydda alltid fr\u00e5n direkt ljus.<\/p>\n<h3>How do I reconstitute GHRP-2?<\/h3>\n<p>F\u00f6lj rekonstitueringsproceduren ovan. Tills\u00e4tt bakteriostatisk vatten l\u00e4ngs sidov\u00e4ggen p\u00e5 flaskan (inte direkt p\u00e5 den lyofiliserade kakan), svirla f\u00f6rsiktigt och l\u00e5t st\u00e5 i 2\u20135 minuter f\u00f6r fullst\u00e4ndig uppl\u00f6sning. Skaka inte flaskan. En korrekt rekonstituerad l\u00f6sning \u00e4r klar och f\u00e4rgl\u00f6s. F\u00f6r en 10 mg flaska + 2,0 mL l\u00f6sningsmedel blir arbetskoncentrationen 5 mg\/mL. <strong>inte<\/strong> Skaka flaskan. En korrekt rekonstituerad l\u00f6sning \u00e4r klar och f\u00e4rgl\u00f6s. F\u00f6r en 5 mg flaska + 2,0 mL l\u00f6sningsmedel \u00e4r arbetskoncentrationen 2,5 mg\/mL.<\/p>\n<h3>MedsBase f\u00f6rser retatrutide i lyofiliserade flaskor med 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg och 60 mg. Varje styrka finns i f\u00f6rpackningar med 10 eller 20 flaskor. Alla flaskor levereras med en renhet p\u00e5 99 %+ enligt HPLC och en analyscertifikat p\u00e5 beg\u00e4ran.<\/h3>\n<p>MedsBase carries GHRP-2 Acetate in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial or 20-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request.<\/p>\n<h3>Why is GHRP-2 more potent than GHRP-6?<\/h3>\n<p>The structural difference is the amino acid at position 2 of the hexapeptide \u2014 D-2-naphthylalanine in GHRP-2 versus D-tryptophan in GHRP-6. The naphthyl ring is more lipophilic and slightly larger than the indole ring of tryptophan, producing tighter binding to the hydrophobic pocket of the GHS-R1a receptor. Radioligand-binding assays show approximately 2\u20133-fold higher receptor occupancy at equivalent doses, which translates into a larger GH pulse per unit dose in published preclinical and clinical research.<\/p>\n<h3>Can GHRP-2 be paired with a GHRH analog in research?<\/h3>\n<p>Yes \u2014 this is the canonical synergistic GH-pulse protocol and the basis of the Japanese clinical GH-deficiency diagnostic test. GHRP-2 activates GHS-R1a (PLC\/IP<sub>3<\/sub>\/Ca<sup>2+<\/sup> signalling) while GHRH analogs such as <a href=\"https:\/\/medsbase.com\/sv\/sermorelin\/\">Sermorelin<\/a> eller <a href=\"https:\/\/medsbase.com\/sv\/cjc-1295-with-dac\/\">CJC-1295 med DAC<\/a> activate GHRH-R (adenylyl cyclase\/cAMP\/PKA signalling). The two pathways converge on somatotrophs but use different second-messenger systems, producing additive or synergistic GH release when combined.<\/p>\n<h3>Does GHRP-2 cause side effects in research?<\/h3>\n<p>The principal on-target effects are GH release and (modest) appetite stimulation. Off-target findings include modest cortisol and prolactin increases \u2014 the principal research-relevant confound for clean GH-axis studies \u2014 comparable in magnitude to GHRP-6. Transient flushing or local injection-site reactions are reported. At high doses, GHS-R-mediated effects on cardiac function and blood pressure can be observed. The cortisol\/prolactin signal is the main reason newer-generation selective analogs such as Ipamorelin were developed.<\/p>\n<h3>What is the half-life of GHRP-2?<\/h3>\n<p>In preclinical and clinical research, GHRP-2 has a plasma half-life of approximately 15\u201320 minutes following subcutaneous or intravenous administration \u2014 somewhat shorter than GHRP-6 (~30\u201360 min). The shorter half-life produces a sharper, more reproducible GH pulse that is useful for diagnostic and dose-response research, but requires more frequent dosing for sustained-stimulus research protocols.<\/p>\n<h3>How long does GHRP-2 take to show effects in preclinical research?<\/h3>\n<p>Acute GH pulses are detectable within 10\u201320 minutes of subcutaneous or intravenous administration and peak within 30\u201345 minutes \u2014 faster onset than GHRP-6 due to higher GHS-R1a affinity. Appetite-stimulation effects on food intake are smaller and slower to develop than with GHRP-6. Downstream effects on IGF-1 production and tissue-level GH-axis signalling accumulate over 1\u20134 weeks of regular dosing.<\/p>\n<h3>Can I order GHRP-2 for international shipping?<\/h3>\n<p>Yes. MedsBase ships GHRP-2 worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our <a href=\"https:\/\/medsbase.com\/sv\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Growth-Axis, GH-Release, and Anabolic Research<\/h2>\n<ul>\n<li><a href=\"\/sv\/ghrp-6\/\"><strong>GHRP-6<\/strong><\/a> \u2014 First-generation hexapeptide sibling \u2014 stronger appetite signal, longer half-life<\/li>\n<li><a href=\"\/sv\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Third-generation selective GHS pentapeptide \u2014 clean GH pulse without cortisol\/prolactin<\/li>\n<li><a href=\"\/sv\/cjc-1295-with-dac\/\"><strong>CJC-1295 med DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 canonical synergistic GHRH partner<\/li>\n<li><a href=\"\/sv\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 Shorter-acting GHRH(1-29) analog \u2014 natural GH-pulse research<\/li>\n<li><a href=\"\/sv\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 Long-arginine recombinant IGF-1 analog \u2014 downstream of GH\/IGF axis<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Vidarel\u00e4sning<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore the GH-axis peptide landscape<\/strong><\/p>\n<p style=\"margin: 0;\">Bl\u00e4ddra bland hela <a href=\"https:\/\/medsbase.com\/sv\/peptides\/\"><strong>forskningspeptidkatalogen<\/strong><\/a>, with related GH-axis compounds including <a href=\"https:\/\/medsbase.com\/sv\/ghrp-6\/\">GHRP-6<\/a> for first-generation sibling research, <a href=\"https:\/\/medsbase.com\/sv\/ipamorelin\/\">Ipamorelin<\/a> for clean receptor-selective GHS research, and <a href=\"https:\/\/medsbase.com\/sv\/cjc-1295-with-dac\/\">CJC-1295 med DAC<\/a> for long-acting GHRH research.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Most potent first-generation GHS hexapeptide<br \/>\n\u2705 GHS-R1a \/ ghrelin receptor agonist<br \/>\n\u2705 Sharper GH pulse than GHRP-6<br \/>\n\u2705 Smaller appetite signal than GHRP-6<br \/>\n\u2705 Approved as Pralmorelin in Japan for GH-deficiency diagnostics<\/p>\n<p><strong>GHRP-2 Acetat<\/strong> inneh\u00e5ller syntetiska peptidf\u00f6reningar.<\/p>","protected":false},"featured_media":70954,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6281,6283,5441,6282],"class_list":{"0":"post-70740","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptides","7":"product_tag-ghrp-2","8":"product_tag-kp-102","9":"product_tag-peptide","10":"product_tag-pralmorelin","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product\/70740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/comments?post=70740"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/media\/70954"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/media?parent=70740"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_brand?post=70740"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_cat?post=70740"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_tag?post=70740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}